In this GEN webinar, Dave Lahr, PhD, Senior Director of Bioinformatics at Foghorn Therapeutics, discusses chromatin regulation and epigenetic mechanisms that shape transcriptional responses to ...

Furthermore, disease control by maintenance therapy with rituximab every 3 months is used in patients with follicular lymphoma. LON is a common side effect of rituximab treatment.

The triple combination arm in the ongoing Phase 2a study combines the subcutaneous formulation of BI-1206 and rituximab with Calquence ® (acalabrutinib) in subjects with indolent B-cell non-Hodgkin's ...

BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the Treatment of Non-Hodgkin's Lymphoma ...

Artiva Biotherapeutics Reports Promising Phase 1/2 Data for AlloNK® in Combination with Rituximab for Heavily Pretreated B-cell Non-Hodgkin Lymphoma Patients ...

Long-term results of a phase 3 trial show that early rituximab monotherapy significantly delays the need for new treatment in patients with asymptomatic, low tumour burden follicular lymphoma.

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory ...

Previously known as JNJ-2113, icotrokinra (Protagonist Therapeutics, Johnson & Johnson) has a very specific mechanism of action for the treatment of moderate to severe plaque psoriasis, according ...

Lymphoma causes symptoms of organ failure before death. Learn what patients in palliative or hospice care could experience leading up to death.

Cosmetic preservatives are essential to ensure the safety and effectiveness of these products. The mechanism and significance of studying the mechanism of action of preservatives are important in ...